Eps8 decreases chemosensitivity and affects survival of cervical cancer patients

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1376-1385

  Chen, Yun Ju ^a   Shen, Meng Ru ^a   Chen, Yen Jen ^a   Maa, Ming Chei ^b   Leu, Tzeng Horng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; ONCOPROTEIN; PACLITAXEL; PROTEIN EPS8; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPS8 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; EARLY CANCER; ENZYME ACTIVITY; EPS8 GENE; FEMALE; HELA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOCULATION; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ANIMAL; CELL CYCLE; CELL DEATH; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; MIDDLE AGED; MOUSE MUTANT; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, SCID; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 49849083350     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2388     Document Type: Article

References (40)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
3. Lora HE, Wu T-C. Focus on endometrial and cervical cancer. Cancer Cell 2004;5:533-8.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
5. zur Hausen H. Human papillomaviruses. Annu Rev Biochem 1994;48:427-47.
6. deVillieers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbial Immunol 1994;186:1-12.
7. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
8. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
9. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
10. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006;16:83-97.
11. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
12. 1 cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001;21:4773-84.
13. 1-S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
14. Rowland BD, Bernards R. Re-evaluating cell-cycle regulation by E2Fs. Cell 2006;127:871-4.
15. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
16. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
17. EI-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
18. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 1995;92:8493-7.
19. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypothesis, in vivo veritas. Nat Rev Cancer 2006;6:909-23.
20. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
21. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.
22. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
23. Crook T, Vousden KH, Tidy JA. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell 1991;67:547-56.
24. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
25. Fazioli F, Minichiello L, Matoska V, et al. Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. EMBO J 1993;12:3799-808.
26. Maa M-C, Lai J-R, Lin R-W, Leu T-H. Enhancement of tyrosyl phosphorylation and protein expression of eps8 by v-Src. Biochim Biophys Acta 1999;1450:341-51.
27. Eps8 in Src-mediated transformation. J Biol Chem 2004;279:9875-81.
28. Maa M-C, Lee J-C, Chen Y-J, et al. Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase. J Biol Chem 2007;282:19399-409.
29. Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 1999;96:9557-62.
30. Meissner JD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the Caski, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol 1999;80:1725-33.
31. Maa M-C, Leu T-H. Vanadate-dependent Fak activation is accomplished by the sustained Fak Tyr-576/577 phosphorylation. Biochem Biophys Res Commun 1998;251:344-9.
32. Eps8-mediated ERK activation. Oncogene 2001;20:106-12.
33. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88:5523-7.
34. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
35. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4.
36. Zefrass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 1995;69:6389-99.
37. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92:12146-50.
38. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of cyclin A gene transcription is mediated by a variant E2F binding site. Proc Natl Acad Sci U S A 1995;92:11264-8.
39. Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci U S A 1987;84:1070-4.
40. Yao J, Weremowicz S, Feng B, et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006;66:4065-78.